ClinicalTrials.gg
Sign In
Not yet recruitingNCT06959498Updated May 6, 2025

Long-term Survival of THA After Pelvic and/or Femoral Osteotomy

An observational study in Hip Arthropathy Associated With Other Conditions, Hip Dysplasia and Survival, Prosthesis, sponsored by Central Hospital, Nancy, France. Not yet recruiting. Per ClinicalTrials.gov, last updated 2025-05-06.

Sponsored by Central Hospital, Nancy, France · Observational

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
20
Sex
All
01

Study summary

Analyze the long-term clinical and radiological outcomes of total hip arthroplasty (THA) in patients with hip dysplasia treated by pelvic osteotomy, femoral osteotomy, shelf acetabuloplasty, or a combination of these interventions, performed during childhood or early adulthood. The aim is to understand the impact of these early interventions on THA survival and long-term joint function.

02

Conditions studied

  • Hip Arthropathy Associated With Other Conditions
  • Hip Dysplasia
  • Survival, Prosthesis
03

In context

Hip Dislocation

107 studies on the registry are indexed under Hip Dislocation; 36 are open to participants now.

This study's planned enrollment of 20 is below the median of 120 across 39 observational studies indexed under Hip Dislocation.

Browse Hip Dislocation studies →

Lead sponsor

Central Hospital, Nancy, France is the lead sponsor of 798 studies on the registry; 186 are open to participants now.

Browse Central Hospital, Nancy, France studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male and female patients, with no age limit, operated in the Centre Chirurgical Emile Gallé, Nancy, France, between 1998 and 2010

Inclusion criteria

  • patients who underwent THA between 1998 and 2010 and had a prior surgical treatment for hip dysplasia (pelvic, femoral osteotomy, shelf acetabuloplasty or combined osteotomy)

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pelvic osteotomy or shelf acetabuloplasty

    Total hip arthroplasty after pelvic osteotomy or shelf acetabuloplasty

    Procedure: Total hip arthroplasty

  • Femoral osteotomy

    Total hip arthroplasty after femoral osteotomy

    Procedure: Total hip arthroplasty

  • Combined osteotomy

    Total hip arthroplasty after a combination of pelvic osteotomy or shelf acetabuloplasty, and femoral osteotomy

    Procedure: Total hip arthroplasty

Interventions

  • ProcedureTotal hip arthroplasty

    Total hip arthroplasty

06

What researchers measure

Primary outcomes

  1. survival

    Study of 15 year survival of THA

    Time frame: 20 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2025; primary completion for May 2025, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 6, 2025
StartEst.
May 1, 2025
Primary completionEst.
May 15, 2025
CompletionEst.
Jun 1, 2025
Last update
May 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06959498
Lead sponsor
Central Hospital, Nancy, France
Responsible party
Olivier ROCHE (Dr, Central Hospital, Nancy, France) — Principal investigator
First posted
May 6, 2025
Start date
May 1, 2025 (estimated)
Primary completion
May 15, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
May 6, 2025

Study contacts

Julia Richard
Contact
julia.richard97@gmail.com
+33628749343
Oliver Roche
Contact
o.roche@chru-nancy.fr

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hip Dislocation →

Other studies from this sponsor

Central Hospital, Nancy, France →

Start the discussion